冠心病患者在介入治疗后心绞痛发作时加用尼可地尔的效果研究

Effect study of addition of nicorandil on angina pectoris in patients with coronary heart disease after interventional therapy

目的探究对冠心病患者经介入治疗后心绞痛发作时应用尼可地尔的效果。方法218例实施介入治疗后的冠心病患者,采用随机数字分组法分成参照组和试验组,各109例。参照组患者接受常规药物治疗,试验组患者在常规药物基础上联合尼可地尔治疗。对比两组患者心功能指标[左室舒张末期内经(LVEDD)、左室收缩末期内径(LVESD)及左室射血分数(LVEF)]、心绞痛发生情况、西雅图心绞痛量表(SAQ)评分、临床疗效。结果两组患者治疗前LVESD、LVEDD及LVEF对比未发现明显差异(P>0.05);治疗后,试验组患者LVESD(40.68±1.79)mm与LVEDD(49.83±2.84)mm均小于参照组的(43.84±2.06)、(53.92±3.53)mm,LVEF(50.47±4.52)%高于参照组的(45.64±4.28)%(P<0.05)。两组患者治疗前心绞痛发作次数与持续时间对比未发现明显差异(P>0.05);治疗后,试验组患者心绞痛发作次数(2.15±0.46)次/周少于参照组的(3.86±0.93)次/周,心绞痛持续时间(1.76±0.57)min/次短于参照组的(2.93±0.76)min/次(P<0.05)。试验组躯体活动受限程度、心绞痛发作程度、心绞痛稳定状态、治疗满意程度、对冠心病的认知程度评分分别为(80.59±7.43)、(84.95±5.74)、(79.26±6.84)、(83.94±5.68)、(86.27±4.68)分,均高于参照组的(74.38±6.02)、(75.54±4.21)、(72.15±5.73)、(76.59±4.17)、(78.41±3.82)分(P<0.05)。试验组患者总有效率98.17%高于参照组的90.83%(P<0.05)。结论冠心病患者介入治疗后心绞痛发作时应用尼可地尔可有效缓解心绞痛症状,改善心功能指标,临床疗效显著。

Objective To explore the effect of addition of nicorandil on angina pectoris in patients with coronary heart disease after interventional therapy.Methods 218 patients with coronary heart disease who received interventional therapy were divided into a reference group and an experimental group by random number grouping method,each consisting of 109 patients.Patients of the reference group received conventional drug therapy,while patients of the experimental group received nicorandil on the basis of conventional drug therapy.Patients in both groups were compared in terms of cardiac function indexes[left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)and left ventricular ejection fraction(LVEF)],angina pectoris,Seattle angina questionnaire(SAQ)score,and clinical efficacy.Results Before treatment,there were no significant differences in LVESD,LVEDD and LVEF between the two groups(P>0.05).After treatment,the experimental group had LVESD of(40.68±1.79)mm and LVEDD of(49.83±2.84)mm,which were smaller than(43.84±2.06)and(53.92±3.53)mm in the reference group;LVEF of(50.47±4.52)%in the experimental group was higher than(45.64±4.28)%in the reference group(P<0.05).Before treatment,no significant difference was found in the frequency and duration of angina attacks between the two groups(P>0.05).After treatment,the frequency of angina attacks in the experimental group was(2.15±0.46)times/week,which was less than(3.86±0.93)times/week in the reference group;the duration of angina attacks was(1.76±0.57)min/time,which was shorter than(2.93±0.76)min/time in the reference group(P<0.05).The scores of physical activity restriction,angina attack,angina stabilization,treatment satisfaction and cognition of coronary heart disease in the experimental groups were(80.59±7.43),(84.95±5.74),(79.26±6.84),(83.94±5.68)and(86.27±4.68)points,which were higher than(74.38±6.02),(75.54±4.21),(72.15±5.73),(76.59±4.17)and(78.41±3.82)points in the reference group(P<0.05).The total effective rate of 98.17%in the experimental group was higher than 90.83%in the reference group(P<0.05).Conclusion Nicorandil can effectively relieve the symptoms of angina pectoris in patients with coronary heart disease after interventional surgery,improve the index of cardiac function,and the clinical effect is significant.